AR and prostate cancer: In addition, the potential role of plasma EVs as a predictive tool in castrate-resistant prostate cancer (CRPC) diagnosis and during posttreatment follow-up has been reported: exosomal androgen receptor splice variant 7 (AR-V7) is associated with lower sex steroid levels and a shorter time to progression (median, 16.0 vs. 28.0 months; P = 0.0499) in CRPC patients [73].